Human Albumin for Clinical Outcome in Aneurysmal Subarachnoid Hemorrhages

Inclusion criteria * Age limits of participants will be between 18 and 80 years with either gender (male or female). * Clinical presentation with the first of symptom of aSAH must be within 72 hours before randomization. * Clinical manifestation must be suggestive of aSAH that may include classical thunderclap headache, cranial nerve deficits, changes in level of consciousness, neck rigidity and neurological deficits. * All cases with WFNS grade 1 to 5 (at the time of randomization) will be recruited in the study. * Head computed tomography demonstrates evidence of SAH (graded on Claassen's scale). * Diagnostic cerebral angiography shows a saccular aneurysm/s, consistent with clinical presentation of SAH. * Definitive treatment of ruptured aneurysm/s (with clipping or coiling of combined) must be carried out within 72 hours prior to randomization. * An informed consent by patient or surrogate representative, must be duly signed and dated. Exclusion criteria * Timing of first symptom of SAH cannot be reliably ascertained. * Cerebral angiogram negative SAH. * Cerebral angiography showing mycotic/traumatic/fusiform aneurysm/s. * Symptomatic vasospasm or angiographic (on TCD or CTA) sets in before recruitment within 72 hours. * History of clinical findings/hospitalization due to heart failure within the past 6 months, * Albumin administration prior to randomization in the same hospital admission. * History of acute myocardial infarction (MI) within past 3 months. * Any clinical presentations or electrocardiography (ECG) findings suggestive of acute MI on current admission. * ECG evidence and/or clinical findings of 2nd or 3rd degree heart block or arrhythmias causing hemodynamic changes. * Echocardiogram done before intervention/randomization showing an ejection fraction of \<40%. * A creatinine level of \>2.0 mg/dl or a creatinine clearance of \<50 ml/min * Pregnancy, lactation, or parturition within previous 30 days * Any allergies to any ingredient in human albumin preparation. * A prior severe physical disability (mRS \>2) that may hamper assessment of clinical outcome. * Advanced chronic obstructive pulmonary diseases (with FEV1 \<50%) may manifest as frequent episodes significantly affecting the overall quality of life. * Hepatic failure or suspected liver dysfunction due to deranged liver functions, decreased serum albumin levels, high bilirubin levels with/without peripheral edema and hepatic encephalopathy. * Patient has been already enrolled in another study involving a drug administration. * Patient suffering from terminal diseases with life expectancy \< 6 months * If patient speaks any other language in which consent has not been translated. * In case, patient drops out/withdraws from study or transferred out of state of Qatar and therefore lost to follow up short of 3-month follow up.